Feasibility Blind Spots

The Hidden Factors Derailing Your Enrollment Timelines

Traditional clinical trial feasibility assessments often begin at the country level but often overlook vital information that can be gained through a deeper analysis of sites and investigators—information that directly impacts enrollment outcomes. Considering that nearly 80% of all trials fail to meet enrollment timelines, it’s time to address this critical disconnect.

Is your team still approaching feasibility in sequence—first country, then sites, and finally investigators—when the reality of successful enrollment depends on all three being done simultaneously? What if the countries that look perfect on paper are hiding investigator-level challenges that will derail your enrollment projections? The “Feasibility Gap” between macro-level planning and micro-level realities is costing the industry billions annually in delayed timelines and missed opportunities.

Download our white paper to learn:

• The hidden investigator-level factors that can make or break your enrollment success
• A practical framework for integrating country, site, and investigator insights simultaneously
• Actionable strategies to reduce timeline delays and accelerate patient access to new therapies